Connect with us


Mark Velleca takes over at Black Diamond; Verve Therapeutics separates CMO, CSO posts

Mark Velleca
→ David M. Epstein is out as CEO of cancer player Black Diamond Therapeutics, which is putting chairman Mark Velleca in charge. This is…



Mark Velleca

David M. Epstein is out as CEO of cancer player Black Diamond Therapeutics, which is putting chairman Mark Velleca in charge. This is Velleca’s third CEO post in less than a decade after running G1 Therapeutics (2014-20) and StrideBio (2021-23). Epstein will still be on the board at Black Diamond, a company that hit the scene in 2018 with $20 million from Versant and quickly followed that up with an $85 million Series B in January 2019. Co-founded by Epstein (not to be confused with Seagen’s David R. Epstein) and Elizabeth Buck, Black Diamond made an impressive Nasdaq debut with an IPO that exceeded $200 million in 2020, but layoffs affected 30% of the staff two years later.

Andrew Bellinger

Verve Therapeutics has made an adjustment to the team as Andrew Bellinger concentrates on his CSO duties and Fred Fiedorek steps in as CMO. “Now is the right time to split the CMO and CSO roles with two, complementary industry leaders,” Verve CEO Sek Kathiresan said in a statement. “Verve’s tremendous progress over the last five years has been made possible by Andrew’s significant contributions in his joint role.”

Fiedorek held a series of executive positions in a 13-year span at Bristol Myers Squibb, culminating in his promotion to SVP and head of cardiovascular and metabolic development. He has previous CMO credits at Intarcia — where he also led global regulatory affairs — and Rhythm Pharmaceuticals. While Verve’s base editor VERVE-101 for heterozygous familial hypercholesterolemia is stuck in neutral with a clinical hold in the US, Kathiresan’s crew inked a gene editing deal with Eli Lilly in June. Bellinger had been effectively juggling the CSO and CMO roles since “they started planning their Phase I studies,” a spokesperson tells Peer Review.

Nadir Mahmood

Rezo Therapeutics, a UCSF spinout chaired by ex-Biogen and Vir Biotechnology CEO George Scangos, has tapped Nadir Mahmood as CEO. Interim chief and co-founder Nevan Krogan, the director of UCSF’s Quantitative Biosciences Institute, will shift to the role of president. Mahmood became SVP, corporate development at Nkarta in 2018 and would later be promoted to chief financial and business officer for Paul Hastings’ crew before his first CEO job at Rezo, which made its debut in November 2022. SR One, a16z Bio + Health and Norwest Venture Partners helped lead the $78 million Series A, and Rezo’s co-founders also include Kronos Bio chief Norbert Bischofberger and UCSF’s Kevan Shokat.

Johanna Friedl-Naderer

→ Vir Biotechnology COO Johanna Friedl-Naderer is stepping down on Sept. 29, and an SEC filing says that Vir won’t be looking for a replacement. Friedl-Naderer is a 21-year Biogen veteran who started out as Vir’s CBO, global in March 2022.

→ Shares of Bausch Health $BHC dropped by as much as 9.5% after the announcement that CFO Tom Vadaketh will resign on Oct. 13. In the event that Bausch Health comes up empty in its CFO search, controller and chief accounting officer John Barresi will take over as finance chief.

Lauren White

Elahere maker ImmunoGen has recruited Lauren White as CFO. Peer Review regulars will know that White recently left C4 Therapeutics and Kendra Adams took over as finance chief on Sept. 18. Before she took the C4 job, White had a 10-year career with Novartis and was VP & global head of financial planning and analysis with the Novartis Institutes for BioMedical Research from 2017-21. ImmunoGen is hoping its Phase III data for Elahere in the MIRASOL trial will be enough to cross the finish line in the European market.

Minnie Kuo

BeiGene isn’t the only one that’s reclaimed the rights to a drug involved in a partnership with Novartis. Pliant Therapeutics and the Swiss pharma giant had teamed up on the NASH asset PLN-1474, but Novartis signaled that it was moving away from the indication before it officially pulled the plug on the alliance in February. As Pliant moves forward with its lead program bexotegrast in idiopathic pulmonary fibrosis and primary sclerosing cholangitis, Minnie Kuo has joined the team as chief development officer. Kuo is a Nektar and Gilead clinical operations vet who spent the last six years at Vir; she was promoted to SVP of translational and clinical development operations in 2021.

Eric Schneider

Pablo Legorreta’s Royalty Pharma has tapped Eric Schneider as chief technology officer. The Moody’s and Barclays alum held several leadership positions in his 11 years at Verisk, where he was recently chief data officer and chief technology officer. Royalty took a dip in the gene therapy pool when it forked over $300 million upfront for a 5.1% royalty on net sales of Ferring’s bladder cancer med Adstiladrin. “We’ve always got questions of: ‘When are you going to ever make a gene therapy investment?’” Royalty CFO Terrance Coyne said at the Morgan Stanley Global Healthcare Conference. “And what we said is: We’re going to be patient there. There’s a lot that we still need to understand. But this opportunity came along. The data is really remarkable.”

Lolita Petit

→ Paris-based gene therapy developer Coave Therapeutics has named J&J’s Lolita Petit as CSO. Petit just finished a two-year stint as director of gene therapy and delivery at Janssen and led the ocular platform team while she was with Spark from 2018-21. Coave is testing an AAV-based gene therapy for eye diseases like retinitis pigmentosa with PDE6b mutations. Spark’s Luxturna, on the other hand, was approved for a rare retinal disease that goes after mutations in the RPE65 gene.

→ Sticking with the theme of gene therapies for eye diseases, Nanoscope Therapeutics has introduced Samuel Barone as CMO. Barone had the same gig at Gemini Therapeutics before it merged with Disc Medicine last summer, and he’s the ex-SVP, clinical development for Adverum Biotechnologies. In March, Nanoscope unveiled Phase II data for its retinitis pigmentosa gene therapy MCO-010 that didn’t reach statistical significance.

Pierre-Alain Ruffieux

→ In a double whammy, Lonza lost two execs this week. Amid a drop in sales growth, CEO Pierre-Alain Ruffieux said Monday that he is waving goodbye to the CDMO at the end of this month. Chairman Albert Baehny is taking over for Ruffieux in the interim. Ruffieux spent nearly three years with the company, having jumped aboard in November 2020 from Roche. Meanwhile, Catalent also swooped in and nabbed David McErlane as its new biologics lead. McErlane had served as Lonza’s SVP and business unit head for the company’s bioscience business.

Deborah Moorad

→ Little-known in vivo gene editing biotech CorriXR Therapeutics has appointed Deborah Moorad as CEO. The Dentsply Sirona alum has been a chief executive at Lincoln, NE-based Nature Technology Corp, which was purchased by Aldevron, which was then acquired by Danaher. Moorad’s predecessor, co-founder Eric Kmiec, slides into the role of CSO at the ChristianaCare spinout.

John Orwin

Atreca president and CEO John Orwin is replacing Frazier managing partner Jamie Topper as chairman of the board at San Diego-based AnaptysBio. Orwin, the new chairman of CARGO Therapeutics, will also be principal financial officer for Atreca after CFO Herb Cross headed for the exit. Topper is giving up his seat on the board after nearly 16 years, eight of those as chairman, and he’ll be an advisor until the first quarter of 2024.

Birge Berns

Marie-Louise Fjällskog is leaving her role as CMO of Faron Pharmaceuticals, but she will stay with the company as a board member. Longtime J&J vet Birge Berns is succeeding Fjällskog as interim medical chief and will work out of the UK for the Finnish cancer biotech. Fjällskog came to Faron from her CMO post at Sensei Biotherapeutics in January 2022.

Steven Mennen

Ipsen’s acute myeloid leukemia partner Accent Therapeutics is putting an emphasis on three new execs this week: Jason Sager (CMO) is the ex-medical chief at Ikena Oncology — back when it was known as Kyn Therapeutics — and has also worked for Genentech, Novartis and Sanofi; Steven Mennen (VP of preclinical development) is a 10-year Amgen vet who left Fulcrum Therapeutics in April after four years as head of CMC; and Bayer alum Stuart Ince (VP of program leadership) has served as VP of program management with Tango Therapeutics.

→ Chaired by Gossamer Bio CEO Faheem Hasnain, Ann Arbor, MI-based thyroid eye disease biotech Sling Therapeutics has selected Raymond Douglas as CSO. Douglas is familiar with the area from his eight years at the University of Michigan as an ophthalmology professor and director of the school’s thyroid eye center. He’s an oculoplastic surgeon who has a private practice in Beverly Hills and was in charge of the orbital and thyroid eye disease programs at Cedars-Sinai.

Gerhard Hagn

→ While we’re thinking of thyroid eye disease, Tourmaline Bio is testing its lead candidate TOUR006 in the same indication and has welcomed Gerhard Hagn as SVP, head of commercial and business development. Hagn had a scrollable list of positions in a 20-year period at Pfizer before he moved to Gilead in 2019 as VP, head of inflammation, global commercial strategy. Starting in 2021, he expanded his role by leading Gilead’s liver franchise as well.

Sam Whiting

Tempest Therapeutics CMO Sam Whiting has taken on the additional role of R&D chief. Peer Review informed you about Whiting’s original appointment back in the fall of 2020, when he succeeded Tom Dubensky as Tempest’s medical leader. The California biotech touted Phase Ib/II data in April that showed seven of 40 patients had a confirmed response to its liver cancer treatment TPST-1120 in a combo with Tecentriq and Avastin, while only three of 29 patients had a confirmed response to Tecentriq and Avastin alone.

Daybue maker Acadia Pharmaceuticals has picked up Albert Kildani as SVP, investor relations and corporate communications. At Halozyme, another San Diego biotech, Kildani was the investor relations and corporate communications leader for nearly four years. Daybue made history in March by becoming the first-ever drug to receive an FDA approval for Rett syndrome.

John Yee

John Yee has been named SVP, medical affairs at Apnimed, the sleep apnea biotech that rang in 2023 with a $79.7 million raise that was stapled on to the original $62.5 million Series C in May 2022. The AstraZeneca and Vertex medical affairs vet is coming off a six-month sabbatical after three years as CMO of Sobi North America.

Gwyn Bebb

→ The CRO Parexel has rolled out the welcome mat for Gwyn Bebb as SVP and global therapeutic area head, oncology. Bebb joins the Durham, NC-based team from Amgen, where he was clinical research medical director in early- and late-stage oncology drug development. Bebb’s résumé also sports a stint as a professor at the department of medicine at the University of Calgary.

Constanze Guenther

ImmunOs Therapeutics, an immuno-oncology player that bagged a $74 million Series B in June 2022, has enlisted Constanze Guenther as SVP, CMC and technical development. Guenther ends her 13-year run at Novartis, where she was global portfolio head, cell therapy and also oversaw the manufacturing of Kymriah in Europe.

→ Amgen sales vet Marc-Andre Goldschmidt has landed at Amsterdam-based Avanzanite Bioscience as country manager of Germany. Goldschmidt was elevated to national sales manager of neurology during his six years at Alexion.

Ian Smith

→ After disappointing data for its Dravet syndrome drug STK-001 caused its shares $STOK to sink in July, Stoke Therapeutics has added former Vertex CFO and COO Ian Smith to the board of directors. Smith chairs the board at Solid Bio and is a senior advisor for Bain Capital Life Sciences.

Daphne Karydas

Flare Therapeutics president and CFO Daphne Karydas has picked up a pair of board appointments at Mineralys Therapeutics and Compass Pathways. Glenn Sblendorio, the former CEO of Astellas sub Iveric Bio, will join Karydas on the board of directors at Mineralys, the hypertension biotech that made a February debut on the Nasdaq in a once-barren IPO environment. New listings are popping up as market conditions gradually improve, like the ones we’ve seen with Neumora, RayzeBio and others.

→ Ex-Kymab CEO Simon Sturge has clinched a spot on the board of directors at Galapagos that was vacated by Mary Kerr. Sturge chairs the board at MoonLake Immunotherapeutics, the maker of an IL-17 inhibitor for hidradenitis suppurativa that has shown some promise in Phase II.

→ J&J’s bispecific partner Xencor has elected Barbara Klencke to the board of directors. Klencke was the CMO and chief development officer for Sierra Oncology until it was purchased by GSK for $1.9 billion, a deal that’s bearing fruit with the approval of JAK inhibitor Ojjaara, formerly known as momelotinib.

Read More

Continue Reading


Israel’s Three ‘No Good’ Options When Dealing With Hamas

Israel’s Three ‘No Good’ Options When Dealing With Hamas

Israel has ordered more than a million people to leave the north of Gaza ahead of…



Israel's Three 'No Good' Options When Dealing With Hamas

Israel has ordered more than a million people to leave the north of Gaza ahead of a potential ground assault intended to squash Hamas following attacks on southern Israel. The gloves are off for Israel, and such an invasion could destabilize the region. 

Louis-Vincent Gave, the chief executive of Gavekal Research based in Hong Kong, penned a note at Gavekal Research on Monday titled "When There Are No Good Options," addressing Israel's three potential strategies in handling Hamas.

Gave writes in the first option, Israel could heavily bomb Gaza, which could lead to significant civilian casualties and the potential eradication of Hamas, reminiscent of the devastation in Dresden or Tokyo in 1945. This approach, however, comes with severe consequences. Firstly, it might provoke vast public protests and alienate Israel's Western allies. More critically, it could unify Arab nations against Israel, drawing support from countries like Turkey and Iran. This may pave the way for an expanded conflict and heightened terrorism, especially given the current arms proliferation due to Afghanistan and the Ukraine-Russia conflict. This volatile scenario could destabilize financial markets, leading to surging oil prices, plummeting bonds, increased inflation, and elevated investment risks.

The second option for Israel is to avoid large-scale bombings but deploy Israel Defense Forces to target Hamas' infrastructure and leadership. While this approach may reduce widespread devastation, it would still result in significant civilian casualties. Urban warfare is challenging, as evidenced by historical events like the capture of Berlin in 1945. Hamas' strategy might be to provoke a street battle in Gaza, questioning the IDF's capability and reliability. Given the rapid dissemination of information on social media, public tolerance for casualties might be limited, pushing for a negotiated resolution. Engaging in such an operation and subsequently retreating could be perceived as an Israeli defeat. 

The third option is for Israel to adopt a patient approach, possibly targeting Hamas' leadership surgically, similar to actions taken against groups like Black September following the 1972 Munich tragedy. However, maintaining the 300,000 conscripts recalled to their units in this scenario would be costly.

Gave noted world leaders are mostly favoring Israel adopting option three. Yet, after the recent incidents in southern Israel, this approach might be challenging for the Israelis to accept because their instinct is to retaliate and confront the terrorist group.

"As I write, Israel has said that it will delay any large-scale move into Gaza, which could indicate that it is leaning towards a third option (by far the least worst for Gaza's civilian population and for the rest of the world)," Gave said, adding markets appear to be pricing in option three:

  1. Oil prices are moderately increased, with the near-term WTI contract moving from US$83/bbl to US$87/bbl, but they're still below early October levels.

  2. US government bond yields have remained stable, even with wars' inflationary tendencies.

  3. Even after the attacks, global equity markets have seen a slight rise.

  4. Gold and silver prices have experienced a modest rebound during these heightened geopolitical risks but remain below summer levels.

  5. This muted response in precious metal prices is peculiar, especially as several Federal Reserve policymakers hinted at halting interest rate hikes, which should boost gold prices.

Gave offered this forecast: "Right now, markets are indicating that we will avoid World War III. Israel's move to delay its Gaza operation suggests they may be right."

Meanwhile, Michael Every, Global Strategist at Rabobank, warned "global security order is crumbling" and provided readers with three brief scenarios for how this war could potentially develop ahead. 

Tyler Durden Tue, 10/17/2023 - 15:20

Read More

Continue Reading


The Triumph Of The Apocalyptics

The Triumph Of The Apocalyptics

Authored by Jeffrey Tucker via The Brownstone Institute,

In the course of almost four years, and really dating…



The Triumph Of The Apocalyptics

Authored by Jeffrey Tucker via The Brownstone Institute,

In the course of almost four years, and really dating back a decade and a half, I’ve managed to read most of the writings of the intellectuals, titans of industry, and government officials who constructed the strange reality of 2020 and after. They wanted to conduct a science experiment on the human population. Because infectious disease knows no borders, they knew for sure it would have to be a global one. 

They had every detail worked out in their models. They knew how far apart people would need to stand. They knew that the best way to stop any common virus from spreading would be total isolation of the whole human population insofar as that was possible. Families could not do that of course but they figured that they could live in different rooms or simply stay six feet apart. If they couldn’t do that, they could mask up. 

It goes without saying – but they said it anyway because their models told them so – that indoor and outdoor venues where people gathered had to be closed (those were the exact words issued by the White House on March 16, 2020). The scheme was deployed first in China, then Northern Italy, then the United States, and the rest of the world fell in line, all but a handful of nations including Sweden, which faced many months of brutal criticism for allowing freedom for its citizens. 

It’s truly hard to imagine what the architects of this barbaric policy believed would happen next. Is it as simple (and ridiculous) as believing that a respiratory virus would just disappear? Or that a potion would show up in time to inoculate the whole population even though no one has ever successfully come up with something like that before? Is that what they believed? 


Or maybe it was just fun or otherwise remuneratively advantageous to try out a grand and global experiment on the human population. Certainly it was profitable for many, even if it wrecked the social, cultural, economic, and political lives of billions of people. Even as I write those words, it’s hard to believe they are not out of some dystopian fiction. And yet this is what happened. 

Almost immediately, the idea of human rights took a back seat. Obviously so. So did the idea of equal freedom: that was immediately on the chopping block. By edict, the human population was divided into categories. It began with essential and nonessential, distinctions drawn from military protocols that suddenly pertained to the whole of the civilian world. 

That was only the beginning of the stark divisions. The stigmatization of the sick began immediately too. Were they sick because they were insufficiently compliant? Did they disobey the protocols? In a hundred years of public health, we’ve not seen this level and scale of demarcation. Some of this was attempted during the AIDS crisis (pushed by none other than Anthony Fauci) but not this aggressively or comprehensively. 

In those days, you could feel the concern for basic rights and freedom slipping, and with it the moral conscience of the public mind. From the beginning, it felt like martial law and the population was being divided: sick vs. well, compliant vs. noncompliant, essential vs non-essential, elective surgeries vs. emergencies needing medical services. And so on. 

And this expanded dramatically over the coming months. When face coverings came along, it was masked vs unmasked. When some states started opening, it became red vs. blue. Us vs. them. 

When the vaccine came along, the ultimate division hit, piling upon and swamping all the others: vaccinated vs. unvaccinated. The mandates massively disrupted the labor force. The public accommodations of whole cities were shut off to the unvaccinated, so that noncompliant citizens could not go to restaurants, bars, libraries, theaters, or other public places. Even houses of worship went along even though they didn’t have to, breaking their congregations into two parts. 

Behind all of this was a political motive that traces to a text that every high expert still celebrates as a prescient and decisive refutation of liberal values: Carl Schmitt’s Concept of the Political from 1932. This essay is utterly dismissive of human rights on grounds that such notions do not sustain robust states. He was of course a Nazi jurist and his thought laid the groundwork for the demonization of the Jews and the march of the totalitarian state. 

In Schmitt’s mind, the friend/enemy distinction is the best method of rallying the people around a grand cause that gives life meaning. This impulse is what gives strength to the state. He goes further: the friend/enemy distinction is best ignited in the reality of bloodshed:

“The state as the decisive political entity possesses an enormous power: the possibility of waging war and thereby publicly disposing of the lives of men. The jus belli contains such a disposition. It implies a double possibility: the right to demand from its own members the readiness to die and unhesitatingly to kill enemies.”

If for years, you have asked the question “Where does this end?” we now have our answer, which seems inevitable in retrospect: war. We are looking at the deaths of innocents and probably this as just the beginning. The lockdowns broke not only the old moral codes and agreed-upon limits to state power. It broke the human personality and spirit the whole world over. It gave rise to a bloodlust that was barely beneath the surface. 

States went crazy in bullying and dividing their citizens. It happened nearly everywhere but Israel was a leading case in point, as Brownstone has pointed out repeatedly. The citizenry has never been more divided and the state never more distracted from security concerns. The delicate peace was shattered in shocking ways on October 7, 2023 in a ghastly attack that revealed the worst security failure in the vulnerable state in its history. 

That incident then encouraged and further unleashed the apocalyptics, whole peoples determined to take the next step in the dehumanization of the population and the use of appalling means of doing the unthinkable: extermination, a word now thrown around as if it is fine and normal to speak this way. This conflict has now reached further into the politics of every country and down to every civic association, communities of intellectuals, and personal friendship. As Schmitt might have loved – and what Bret Weinstein calls Goliath (the unity of administrative state, media, corporate power, and elite tech platforms) surely celebrates – everyone is being turned into the category of friend and enemy. 

We are reminded at last of how incredibly fragile civilization – and the peace and freedom that gives rise to it – truly is. We should worry that in the drama of the moment, the history recounted above will be discarded from human memory. The plans for virus eradication failed so badly that many of its perpetrators are desperate for a dramatic change of subject so that they can avoid responsibility. Again, this is the desire, and it might even be the plan. 

This simply cannot be allowed to happen. Those of us with memories of civilized life, including universal rights and freedoms, cannot stay silent or get emotionally drawn in to the point that we are willing to forget what was done to us, the damage it inflicted on public culture, and the moral conduct a civilized people expect. 

Every war is preceded by a period of demoralization (I don’t matter), demotivation (there is nothing I can do), and dehumanization (those people are not worth saving). From there it is a simple matter of flipping the switch. 

Brownstone was founded in light of the above history to shine a light on higher ideals, not a Schmittian war between friends and enemies but societies of compassion, dignity, freedom, rights, and the exercise of human volition against all threats and uses of violence public and private. This is our guiding light now and always. Apocalypticism builds nothing; it only destroys. It’s the instantiation of the philosophy of The Joker. No nation and no community can survive it. 

Few of us knew or fully understood the depth of depravity just beneath the thin veneer of civilization that had previously dominated the large expanse of our lives. It was the maniacal experiment in disease control only a few years ago that triggered this bout of man’s inhumanity to man. There is a burning need to know how this came about and why, and take measures, now desperate ones, to put back into the Pandora’s box all that was released. 

Tyler Durden Tue, 10/17/2023 - 16:20

Read More

Continue Reading


WTI Extends Gains After API Reports Across-The-Board Inventory Draws

WTI Extends Gains After API Reports Across-The-Board Inventory Draws

Oil prices closed higher on the day, after a roller-coaster ride down…



WTI Extends Gains After API Reports Across-The-Board Inventory Draws

Oil prices closed higher on the day, after a roller-coaster ride down this morning after Russia’s Central Bank reiterated expectations that OPEC+ may consider an increase in output at the beginning of 2024, but that was quickly pushed back on by Russian Deputy Prime Minister Alexander Novak.

Crude traders are also tracking events in Barbados, where Venezuela’s government is expected to sign a deal with the US-backed opposition later on Tuesday. In exchange for a freer presidential election next year, the agreement could pave the way for the US to ease sanctions against the country, potentially boosting oil exports.

“Traders remain on high alert” while oil remains in a holding pattern, said Rebecca Babin, a senior energy trader at CIBC Private Wealth.

“Many investors are not willing to make outright bets on crude in the current environment but are actively buying upside call options in the event crude supply is impacted. It is a low conviction, highly volatile trading environment.”

WTI accelerated its rebound after the missile strike on a Gazan hospital.

After last week's large crude build (and draws at Cushing and in products), all eyes are for any signs of further demand destruction.


  • Crude -4.38mm (+400k exp)

  • Cushing -1.00mm

  • Gasoline -1.58mm (-600k exp)

  • Distillates -612k (-1.2mm exp)

API reports inventory drawdowns across the board with Crude stocks unexpectedly falling 4.4mm barrels (+400k exp) and Cushing getting ever closer to 'tank bottoms'...

Source: Bloomberg

WTI was hovering around $87.20 and extended gains after the draws...

Bloomberg's Javier Blas penned an interesting op-ed, blasting the fact that the Biden administration has allowed the SPR to run so low, saying that this ignorance could not come at a worst time.

Henry Kissinger called it “the economic equivalent of the Sputnik challenge.” 

Exactly 50 years ago today, the US found itself under economic assault after Arab nations weaponized oil, starting a petroleum embargo that brought the global economy to its knees.

Kissinger, vowing America would never be blackmailed again, designed a shield against the oil weapon: the Strategic Petroleum Reserve. A stockpile containing hundreds of millions of barrels of crude, its function was to offset the impact of any future supply disruption, intentional or not. Half a century later, Washington has forgotten that lesson.

The SPR today contains less than half the crude it had at its peak just over a decade ago. At about 350 million barrels, it's at its lowest since 1983. To put what’s left into perspective, the US released about 270 million barrels over the last two years to cap oil prices.

[ZH: For context, there is less than 20 days of supply left to meet current levels of demand... but we know SPR can't go to 'zero' so good luck]

If the SPR is a revolver, it has a final round left in the chamber — and that’s it.

Worth a read...

Tyler Durden Tue, 10/17/2023 - 16:37

Read More

Continue Reading